Protocol Ledger

NCT06411275 · Phase II · COMPLETED

A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise

Interventional Phase II clinical trial protocol NCT06411275 sponsored by Shenzhen HighTide Biopharmaceutical in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-31 Enrollment: 113 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06411275
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)113 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06411275
Protocol FieldVerified Registry Value
NCT IdentifierNCT06411275
Consolidated Lead SponsorShenzhen HighTide Biopharmaceutical
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment113 participants (ACTUAL)
Registered Start Date2022-03-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06411275
Hospital Research SiteLocationSite Profile
Peking University People's HospitalBeijing, ChinaOpen Hospital Dossier ->
The Second Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->
Jinan Central HospitalJinan, ChinaOpen Hospital Dossier ->
Liaocheng People's hospitalLiaocheng, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI